VivoSeq
Other

Drug Therapy

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Drug Therapy is an early-stage landscape with 0 programs across 2 companies. The most active players are Amgen, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

94/100

Attrition Rate

5/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Amgen logo

Amgen

0 programs

PreclinicalEli Lilly logo

Eli Lilly

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

19

clinical trials

Completed16 · 84%
Unknown status2 · 11%
Withdrawn1 · 5%

Clinical Trials

Trial Activity

19 trials

Combined Drug Therapy in Lateral Fragility Fractures of the Femur
Completed·AAzienda Ospedaliero-Universitaria Consorziale Policlinico di Bari·N/A·NCT05183308·50 enrolled
Cognitive and Drug Therapy for Drug-Resistant Depression
Completed·UUniversity of Pennsylvania·N/A·NCT00000376
A Comparison of the Drug Therapy Versus Re-Ablation
Completed·MMeshalkin Research Institute of Pathology of Circulation·Phase 2·NCT01709682·154 enrolled
Duloxetine Versus Duloxetine Plus Non-Drug Therapy for Depression
Completed·Eli Lilly logoEli Lilly·Phase 4·NCT00494377·940 enrolled
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
Completed·Amgen logoAmgen·Phase 2·NCT01375777·411 enrolled
A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000902·217 enrolled
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Completed·Amgen logoAmgen·Phase 3·NCT01763827·615 enrolled
Safety of the Candidate Vaccine C4-V3 Alone or With Interleukin-12 (IL-12) in HIV-Infected Patients Receiving Effective Anti-HIV Drug Therapy
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00005779·12 enrolled
Drug Therapy to Treat Minor Depression
Completed·MMassachusetts General Hospital·N/A·NCT00048815·73 enrolled
Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000923·110 enrolled
Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00038259·21 enrolled
Eval 3-Drug Therapy Diethylcarbamize, Albendazole and Ivermectin That Could Accelerate LF Elimination Outside of Africa
Completed·UUniversity Hospitals Cleveland Medical Center·Phase 2·NCT01975441·182 enrolled
A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy
Completed·AAbbott·Phase 3·NCT00004583·660 enrolled
Drug Therapy for Alcohol Detoxification
Completed·National Institute on Alcohol Abuse and Alcoholism (NIAAA)·Phase 4·NCT00000441
"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
Completed·—·Phase 4·NCT00114933·200 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)